| http://www.w3.org/ns/prov#value | - Glatiramer acetate injection (Copaxone, Teva Pharmaceutical Industries Ltd., Jerusalem, Israel) has been approved by the U.S. Food and Drug Administration (FDA) for the reduction of the frequency of relapses in relapsing remitting MS, including patients who have experienced a first clinical episode and have MRI features consistent with MS. The FDA approved an expanded indication for glatiramer ace
|
